Detailed TRIUMPH-2 results show weight loss with retatrutide
Detailed TRIUMPH-2 phase 3 results put experimental retatrutide in focus for adults with type 2 diabetes and obesity or overweight. Over 80 weeks, mean weight loss in the highest-dose group reached 20.8 percent of starting weight, according to figures released by Lilly; HbA1c also fell. The findings currently rest on the manufacturer’s detailed disclosure and a conference presentation. The drug remains investigational, and more complete published data and regulatory review will inform its clinical place.
Science··Midday
A detailed sponsor disclosure
Eli Lilly released more detailed results from TRIUMPH-2, an 80-week phase 3 program for its experimental medicine retatrutide. Scientific American covered the same announcement. The participants had type 2 diabetes and obesity or overweight. Retatrutide acts on three hormone-receptor pathways, GLP-1, GIP and glucagon, which are involved in appetite and metabolism. These mechanisms provide context for the drug. The announcement describes clinical measurements; it does not establish how much each pathway contributed to the observed changes.[1], [2]
Weight and glucose measures
According to Lilly, mean weight loss reached about 13.5 kilograms in one dose group, 20.6 kilograms in another and 22.5 kilograms in the highest-dose group. The reported comparison-group mean was about 4.2 kilograms. The highest-dose result equaled an average of 20.8 percent of starting body weight. The company also reported a fall in HbA1c, a measure of blood glucose over preceding months. Scientific American relayed the same sponsor-supplied findings. A group mean does not describe each person’s experience; crossing a body-mass-index threshold does not mean all individual health risks disappear.[1], [2]
How far the data reach
These figures were released by the manufacturer and discussed at a medical congress; a full TRIUMPH-2 research paper is not in the current source set. The participants had both type 2 diabetes and excess weight, so the result cannot automatically be extended to people without diabetes. Weight and HbA1c changes also answer different questions from heart attacks, strokes or deaths. Adverse events, treatment discontinuation and longer-term outcomes matter to any eventual assessment. Retatrutide remains investigational, and the disclosure is not a treatment recommendation.[1]
